INO-3107
Recurrent Respiratory Papillomatosis (RRP)
Key Facts
About Inovio Pharmaceuticals
Inovio Pharmaceuticals is a U.S.-based clinical-stage biotech focused on developing DNA-based immunotherapies and vaccines. Its core strategy leverages a proprietary two-part platform—SynCon® for plasmid design and CELLECTRA® for delivery—to advance a pipeline targeting HPV-related diseases, cancer, and infectious diseases. The company's most significant near-term catalyst is the FDA review of its Biologics License Application (BLA) for INO-3107 in recurrent respiratory papillomatosis (RRP), which represents a potential first-in-class DNA medicine approval. With a seasoned leadership team and a history of strategic partnerships, Inovio is positioning itself at the forefront of nucleic acid therapeutics.
View full company profileTherapeutic Areas
Other Recurrent Respiratory Papillomatosis (RRP) Drugs
| Drug | Company | Phase |
|---|---|---|
| PAPZIMEOS (zopapogene imadenovec-drba) | Precigen | Approved |